Inventor · disambiguated record
Gene Kinney
Also filed as: KINNEY GENE · KINNEY GENE G
20 granted patents·20 pending applications·104 citations·filing 2001–2025
94Inventor score
Files withOTHAIR PROTHENA LTD8PROTHENA BIOSCIENCES LTD8BRISTOL MYERS SQUIBB CO3ACTON PAUL2KINNEY GENE2
Top patents by PatentIndex Score
40 records- 0195US11965005B2Multi-epitope vaccine for the treatment of Alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2023·Granted Apr 23, 2024·1 cites·25 claims
- 0292US7780963B2Anti-ADDL antibodies and uses thereofMERCK & CO INC·Filed 2005·Granted Aug 24, 2010·25 cites·14 claims
- 0392US6469042B1Fluoro oxindole derivatives as modulators if KCNQ potassium channelsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Oct 22, 2002·32 cites·12 claims
- 0490US12247056B2Multi-epitope vaccine for the treatment of Alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2024·Granted Mar 11, 2025·0 cites·26 claims
- 0587US11952406B2Multi-epitope vaccine for the treatment of Alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2023·Granted Apr 9, 2024·0 cites·25 claims
- 0687US11945849B2Multi-epitope vaccine for the treatment of Alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2023·Granted Apr 2, 2024·0 cites·25 claims
- 0787US7811563B2Anti-addl antibodies and uses thereofUNIV NORTHWESTERN·Filed 2005·Granted Oct 12, 2010·9 cites·14 claims
- 0885US11692024B2Methods of treating AL amyloidosisPROTHENA BIOSCIENCES LTD·Filed 2020·Granted Jul 4, 2023·2 cites·42 claims
- 0984US7731962B2Anti-ADDL monoclonal antibody and use thereofMERCK & CO INC·Filed 2006·Granted Jun 8, 2010·8 cites·12 claims
- 1081US8383113B2Anti-ADDL antibodies and uses thereofUNIV NORTHWESTERN·Filed 2012·Granted Feb 26, 2013·4 cites·12 claims
- 1180US2025282838A1Multi-Epitope Vaccine for the Treatment of Alzheimer's DiseaseOTHAIR PROTHENA LTD·Filed 2025·Application pending·0 cites
- 1276US12240894B2Methods of treating AL amyloidosisPROTHENA BIOSCIENCES LTD·Filed 2023·Granted Mar 4, 2025·0 cites·25 claims
- 1376US8889138B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Nov 18, 2014·3 cites·12 claims
- 1476US8128930B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Mar 6, 2012·3 cites·13 claims
- 1576US8105593B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2010·Granted Jan 31, 2012·2 cites·12 claims
- 1676US6831080B2Cinnamide derivatives as KCNQ potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 14, 2004·11 cites·27 claims
- 1776US2023183304A1Multi-Epitope Vaccine for the Treatment of Alzheimer's DiseaseBARBOUR ROBINOO·Filed 2021·Application pending·0 cites
- 1875US8420093B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2012·Granted Apr 16, 2013·2 cites·12 claims
- 1972US7850973B2Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's diseaseMERCK SHARP & DOHME·Filed 2006·Granted Dec 14, 2010·1 cites·10 claims
- 2071US9272030B2Use of tau to monitor immunotherapyBLACK RONALD·Filed 2011·Granted Mar 1, 2016·1 cites·16 claims
- 2168US2010144858A1Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulatorCONN P JEFFREY·Filed 2009·Application pending·0 cites
- 2267US2025188159A1Methods of treating al amyloidosisPROTHENA BIOSCIENCES LTD·Filed 2025·Application pending·0 cites
- 2358US2021079078A1Compositions for Treating AmyloidosisPROTHENA BIOSCIENCES LTD·Filed 2020·Application pending·0 cites
- 2458US2025345418A1Methods of treating al amyloidosisPROTHENA BIOSCIENCES LTD·Filed 2023·Application pending·0 cites
- 2557US2023355756A1Alpha-synuclein vaccine for the treatment of synucleinopathiesPROTHENA BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 2657US2023355729A1Multiepitope vaccine for the treatment of alzheimer's diseaseBARBOUR ROBIN·Filed 2021·Application pending·0 cites
- 2757US2025186567A1Multiepitope vaccine for the treatment of alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2021·Application pending·0 cites
- 2856US2023364210A1ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASEOTHAIR PROTHENA LTD·Filed 2021·Application pending·0 cites
- 2956US2023302127A1Tau vaccine for the treatment of alzheimer's diseaseOTHAIR PROTHENA LTD·Filed 2021·Application pending·0 cites
- 3055US2023391859A1Anti-transthyretin antibodies and methods of use thereofNOVO NORDISK AS·Filed 2021·Application pending·0 cites
- 3154US2006166972A1Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulatorCONN P J·Filed 2004·Application pending·0 cites
- 3253US2025084153A1Methods of treating al amyloidosisPROTHENA BIOSCIENCES LTD·Filed 2022·Application pending·0 cites
- 3352US2011002949A1Vaccine for the treatment of alzheimer's diseaseSAVAGE MARY J·Filed 2009·Application pending·0 cites
- 3450US2003215916A1Novel imidazoline receptor homologsFiled 2003·Application pending·0 cites
- 3547US2019169280A1Compositions for treating amyloidosisKINNEY GENE G·Filed 2017·Application pending·0 cites
- 3644US2011052611A1Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's diseaseGARSKY VICTOR M·Filed 2010·Application pending·0 cites
- 3743US11191832B2Monitoring immunotherapy of Lewy body disease from constipation symptomsPROTHENA BIOSCIENCES LTD·Filed 2014·Granted Dec 7, 2021·0 cites·27 claims
- 3842US6855829B23-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseaseBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 15, 2005·0 cites·8 claims
- 3940US2002183335A12, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulatorsFiled 2002·Application pending·0 cites
- 4035US2002161191A1Novel Imidazoline receptor homologsFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →